Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
Sabine Haggenburg,Quincy Hofsink,Birgit I Lissenberg-Witte,Annoek E C Broers,Jaap A van Doesum,Rob S van Binnendijk,Gerco den Hartog,Michel S Bhoekhan,Nienke J E Haverkate,Judith A Burger,Joey H Bouhuijs,Gaby P Smits,Dorine Wouters,Ester M M van Leeuwen,Hetty J Bontkes,Neeltje A Kootstra,Sonja Zweegman,Arnon P Kater,Mirjam H M Heemskerk,Kaz Groen,Tom van Meerten,Pim G N J Mutsaers,Tim Beaumont,Marit J van Gils,Abraham Goorhuis,Caroline E Rutten,Mette D Hazenberg,Inger S Nijhof JAMA oncology（2022）
摘要
EudraCT Identifier: 2021-001072-41.
更多查看译文
关键词
immunocompromised patients,antibody,hematologic cancers
AI 理解论文
溯源树
样例
